[Switching to quetiapine fumarate monotherapy for treatment-resistant schizophrenia: a report of five cases].

نویسندگان

  • Tomás Sánchez-Araña Moreno
  • Sergio Ruiz-Doblado
  • Julián Elorza-Guisasola
  • Eulalio Valmisa-Gómez de Lara
چکیده

We assessed the efficacy and tolerance of switching to monotherapy with quetiapine fumarate (QF) in treatmentresistant schizophrenia with other antipsychotics, including atypical ones. QF treatment was maintained for 8 weeks. The PANSS scores improved at least 40% over this period. QF was well tolerated without the presence of serious adverse effects. Switching to QF in these patients may therefore be considered as optimal in response and tolerance. Key words: Schizophrenia, Treatment-resistant, Antipsychotics, Quetiapine fumarate.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

The management of schizophrenia: focus on extended-release quetiapine fumarate

Effective management of schizophrenia remains a significant clinical challenge. While antipsychotic medications have proven efficacy in this disease, there remains an opportunity to further improve symptom control and long-term relapse prevention. Also, a number of factors, including tolerability and complex dosing regimens, can result in nonadherence to medication. Quetiapine is an atypical an...

متن کامل

Update on extended release quetiapine fumarate in schizophrenia and bipolar disorders

The atypical antipsychotic quetiapine fumarate is available both as an immediate release (IR) and as an extended release (XR) formulation allowing flexibility of dosing for individual patients. Approved uses of quetiapine XR include the treatment of schizophrenia (including maintenance therapy for prevention of relapse), the treatment of bipolar disorder (manic and depressive episodes), and the...

متن کامل

Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis

BACKGROUND This study compared hospital admission rates among adult patients with schizophrenia who switched to antipsychotic monotherapy with lurasidone or quetiapine. METHODS This retrospective cohort study used U.S.-based Truven Health MarketScan® Medicaid Multi-State Database (April 2010 through December 2012) and MarketScan® Commercial Claims and Encounters Database (April 2010 through O...

متن کامل

Biology of Schizophrenia: Is Treatment Refractoriness Synonymous with Severity of Illness [A.K.A. Is This a Drug Efficacy Problem or an Expression of Severe Illness?]

Wewould like to start this chapter by describing three severe cases of schizophrenia where treatment resistance developed at different time points of the evolution or natural history of disorder. Case report 1—AB is a man of 34 years who developed his first psychotic symptoms at the age of 17 years. He has a history of neurodevelopmental abnormalities such as birth complications and motor and l...

متن کامل

Long-term efficacy and tolerability of quetiapine in patients with schizophrenia who switched from other antipsychotics because of inadequate therapeutic response—a prospective open-label study

BACKGROUND While the frequency and importance of antipsychotic switching in patients with schizophrenia, there is insufficient evidence with regard to switching strategy. Quetiapine is one of the drugs of choice for switch because of its unique receptor profile. However, there were no data on the long-term clinical and neurocognitive effect of quetiapine in patients who had responded inadequate...

متن کامل

ذخیره در منابع من

ذخیره در منابع من قبلا به منابع من ذحیره شده

{@ msg_add @}


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Actas espanolas de psiquiatria

دوره 39 5  شماره 

صفحات  -

تاریخ انتشار 2011